文献速递儿童呼吸儿童感染儿童内分泌与遗传代谢

儿科药物治疗进展与局限:基层儿科医生视角

Pediatric Pharmacology for the Primary Care Provider: Advances and Limitations.
PubMed 文献 · Pediatrics · 2024-01-01

美国超过五分之一儿童使用处方药,但超说明书用药仍普遍。该综述基于2018至2023年药品标签变更、已发表文献及Clinicaltrials.gov信息,梳理了哮喘、肥胖及相关疾病、精神心理疾病、感染和皮肤疾病等领域的儿科药物治疗进展,并讨论了成本与非药物治疗等影响因素。

要点

  • 2018至2023年哮喘、肥胖、精神心理、感染和皮肤疾病领域有儿科药物进展。
  • 部分新药基于对疾病机制的深入理解而开发,部分老药基于新数据扩展了标签。
  • 成本和非药物治疗是影响儿科药物使用的重要因素。

核心结论

  • 儿科特异性药物开发工作虽有待完善,但将增加常用处方药的循证标签指导,并通过安全有效用药改善儿童结局。

研究设计与样本

  • 综述,使用2018至2023年药品标签变更信息、已发表文献和Clinicaltrials.gov数据。

主要发现

  • 综述讨论了哮喘、肥胖及相关疾病、精神心理疾病、感染和皮肤疾病等治疗领域的儿科药物治疗进展。
  • 部分新药基于对疾病机制的更深入理解而开发,部分老药基于新获得的数据扩展了标签。

临床怎么用

  • 儿科基层医生可关注2018至2023年标签变更和文献证据,在哮喘、肥胖、精神心理、感染和皮肤疾病等领域应用循证药物信息。

局限性

  • 综述未系统报告各治疗领域的具体研究样本量、效应量或证据等级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite >1 in 5 children taking prescription drugs in the United States, off-label drug use is common. To increase the study of drugs in children, regulatory bodies have enacted legislation to incentivize and require pediatric drug studies. As a result of this legislation, novel trial approaches, and an increase in personnel with pediatric expertise, there have been numerous advancements in pediatric drug development. With this review, we aim to highlight developments in pediatric pharmacology over the past 6 years for the most common disease processes that may be treated pharmacologically by the pediatric primary care provider. Using information extracted from label changes between 2018 and 2023, the published literature, and Clinicaltrials.gov, we discuss advances across multiple therapeutic areas relevant to the pediatric primary care provider, including asthma, obesity and related disorders, mental health disorders, infections, and dermatologic conditions. We highlight instances in which new drugs have been developed on the basis of a deeper mechanistic understanding of illness and instances in which labels have been expanded in older drugs on the basis of newly available data. We then consider additional factors that affect pediatric drug use, including cost and nonpharmacologic therapies. Although there is work to be done, efforts focused on pediatric-specific drug development will increase the availability of evidence-based, labeled guidance for commonly prescribed drugs and improve outcomes through the safe and effective use of drugs in children.

来源:Pediatrics,查看原文。版权归原作者所有。

引用

  1. Thompson EJ, Wood CT, Hornik CP, et al. Pediatric Pharmacology for the Primary Care Provider: Advances and Limitations. Pediatrics. 2024. PMID: 38841764. doi:10.1542/peds.2023-064158

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。